On January 23, 2026, Harvard Bioscience, Inc. announced a plan called Project Viking to consolidate its manufacturing operations, closing its Holliston, MA facility and relocating production to Minneapolis, MN and other locations in Europe, aiming for $3 million in savings in 2027 and $4 million annually thereafter. The restructuring will incur charges between $3.4 and $4.4 million, with completion expected by mid-2027.